Deepwise Healthcare's Hip AI Software Receives NMPA Class III Certificate, the First in China
Deepwise Healthcare's hip X-ray image-assisted assessment software has been approved for the NMPA Class III medical device registration certificate, making it the first hip AI product in China to receive a Class III certificate. The product targets skeletal developmental abnormalities in infants and young children such as developmental dysplasia of the hip, and can perform intelligent analysis and measurement of anteroposterior hip X-ray images; physicians can complete image review, automatic AI analysis, result verification, and structured illustrated report output on the browser side. The product complements Deepwise Healthcare's previously certified bone age AI product, and its liver CT AI product was also approved last week.
Why read this
AI score 51
China's first Class III certificate for hip AI has been granted, which can be viewed alongside the company's previously certified bone age and liver CT products to gauge the pace of its pediatric AI product matrix.
Topics
Body · AI translation
Add new crowd-testing promotional copy Add new crowd-testing promotional copy end Add App-exclusive traffic guidance
November 16, 2026 16:08:14
Recently, Deepwise's hip joint X-ray image-assisted evaluation software officially obtained the Class III medical device registration certificate from the National Medical Products Administration (NMPA), becoming the first hip joint AI product in China to receive an NMPA Class III certificate. The product focuses on developmental dislocation of the hip and other skeletal developmental abnormalities that occur frequently in infants and young children, and can perform intelligent analysis and precise measurement of anteroposterior hip X-ray images, improving the diagnostic and evaluation efficiency of pediatric hip developmental abnormalities. The development of this product, supported by the team of Yu Gang / Zhao Guoqiang at the Children's Hospital, Zhejiang University School of Medicine, closely addresses the public welfare needs of children's growth and development and skeletal health. The approval of this hip joint AI product complements Deepwise's bone age AI product, which previously obtained an NMPA Class III certificate, forming a pediatric AI product matrix covering children's growth and development evaluation and DDH screening and evaluation. This is a landmark breakthrough for Deepwise, which has consistently adhered to physician-engineer collaborative innovation, in the pediatric intelligent diagnosis and treatment track, further promoting the downward extension of high-quality pediatric imaging capabilities and safeguarding children's healthy growth. Following last week's approval of its liver CT AI product, Deepwise has once again obtained a major Class III certificate. Consecutive certifications in a short period fully validate the company's mature and robust full-chain medical AI system capabilities, its sustained high-quality product conversion output, and demonstrate Deepwise's core competitiveness in the medical AI track.
Developmental dysplasia of the hip (DDH, commonly known as developmental dislocation of the hip) is the most common musculoskeletal developmental abnormality in infants and young children and is a key screening disease for children's skeletal health. The disease has an insidious course and changes dynamically, often lacking typical external manifestations in the early stage. If not identified and intervened in time, it may gradually progress with growth and development, causing subluxation and dislocation of the hip joint, and in the long term is prone to causing limping, leg length discrepancy, and early-onset hip osteoarthritis, seriously affecting the patient's lifelong motor function and quality of life. DDH diagnosis and treatment emphasize "early detection and early intervention"; the earlier the intervention, the simpler the treatment plan and the better the prognosis. Once delayed to an advanced stage, complex surgical correction is often required, placing a heavy burden on families. For patients older than 6 months, hip X-ray imaging evaluation is the core clinical diagnostic method, but traditional manual film reading relies on physician experience and requires manual measurement of multiple key indicators; measurement consistency is easily affected by physician experience and proficiency, and diagnostic capabilities at primary healthcare institutions are uneven, posing challenges to standardized and inclusive screening. Targeting this clinical pain point, with strong support from the Children's Hospital, Zhejiang University School of Medicine, Deepwise has joined forces with clinical experts in pediatrics and radiology to carry out sustained physician-engineer collaborative research and has launched a hip joint X-ray image-assisted evaluation software based on deep learning, providing a standardized and reusable intelligent assisted evaluation tool for early screening and early diagnosis of infant hip developmental abnormalities. The product uses AI capabilities to address the homogenization shortcomings of imaging evaluation, helping standardize measurement standards, reducing human interpretation differences, and enabling high-quality DDH evaluation capabilities to reach more medical institutions, safeguarding infant skeletal health.
The product's functional modules, including deep learning-based hip dislocation evaluation and text-image reports, allow physicians to directly complete image retrieval, preprocessing, AI automatic analysis, result review, and structured text-image report output in the browser, adapting to lightweight in-hospital deployment and supporting system parameter configuration, hierarchical permission control, and full traceability of operational behavior, meeting hospitals' regulatory requirements for data security, process quality control, and informatization management. The product is used for the display, processing, measurement, and analysis of anteroposterior hip X-ray images and, after excluding secondary hip dislocation, can be used for auxiliary evaluation prompts of pediatric hip dislocation.
Deepwise continues to advance physician-engineer integrated innovation in the pediatric field with institutions at all levels, forming a systematic layout at the levels of scientific research and product conversion. Previously, research results by Deepwise and the Yu Gang/Zhao Guoqiang research group at the Children's Hospital, Zhejiang University School of Medicine on AI-assisted diagnosis of pediatric hip dysplasia were accepted by the internationally renowned journal Frontiers in Pediatrics; the company also jointly participated in the "14th Five-Year Plan" National Key R&D Program project "Construction of a Child Health Support Platform Based on Big Data and Artificial Intelligence Technology," undertaking research on topics related to a multimodal child health big data AI training platform. At the same time, the project "Key Technology Innovation and Application of Artificial Intelligence-Assisted Diagnosis of Pediatric Diseases," completed by Deepwise together with the Children's Hospital, Zhejiang University School of Medicine, won the Second Prize of the Zhejiang Provincial Science and Technology Progress Award, and related results have been implemented in more than 2,000 medical institutions nationwide, benefiting tens of millions of pediatric patients. Sustained clinical research accumulation has laid a solid foundation for the R&D, validation, and registration conversion of pediatric AI products, opening the path from cutting-edge technology to inclusive clinical application, and continuously empowering the high-quality development of children's health through AI technology.
Deepwise has long focused on the field of children's growth and developmental abnormalities. Previously, its bone age AI software and intelligent bone age instrument were successively approved as the first domestic products of their kind to obtain NMPA Class III certificates. Relying on multiple certified products, the company has now formed a rich pediatric AI product matrix and, combined with the Deepwise TrioData X medical data large model capability platform, has built a multimodal AI capability system oriented to real clinical scenarios. The platform creates a one-stop digital and intelligent solution covering intelligent imaging screening, quantitative assisted diagnosis, follow-up intervention, and full-cycle data management: on the one hand, it automatically identifies imaging indicators and outputs standardized quantitative results to improve interpretation consistency; on the other hand, it builds structured child health records to support regional screening coordination, long-term developmental trend tracking, and closed-loop management of rehabilitation intervention, empowering diverse scenarios such as hospitals, maternal and child health institutions, and school screening, and building a precise, continuous, and traceable AI diagnosis and treatment management system for children's health. At present, this intelligent diagnosis and treatment platform for children's growth and development has been implemented in Xinjiang, Shanghai, Nanjing, Hangzhou, and other places, continuously improving the quality and efficiency of children's growth and development screening and further expanding the coverage of high-quality children's health services.
Looking ahead, Deepwise will continue to anchor itself to the rigid clinical needs of maternal and child health, rely on its self-developed vertical-domain medical large model and multimodal agent technology, deepen physician-engineer collaborative innovation, accelerate pediatric AI technology research, product iteration, and large-scale implementation, support the digital and intelligent upgrade of children's skeletal health and growth and development management, continuously improve the full-cycle intelligent management system for children covering screening, evaluation, follow-up, and intervention, and promote the downward extension of high-quality pediatric medical resources. The company will adhere to a clinical-value-oriented approach, empower children's health through medical AI, and safeguard the healthy growth of millions of children. Statement: This is an exclusive article of Sina.com; reproduction without authorization is prohibited. tech_web_article_v2015_block_bottom Non-targeted 300*250 button 17/09 wenjing begin
Non-targeted 300*250 button end